Elan veterans grab $34m for neurodegenerative diseases

The only two employees at the virtual biotechnology company Annexon Biosciences are former Elan Pharmaceuticals business and research executives Doug Love and Ted Yednock, but they raised $34m in a Series A-1 venture capital funding round to advance drugs for neurodegenerative diseases.

The only two employees at the virtual biotechnology company Annexon Biosciences are former Elan Pharmaceuticals business and research executives Doug Love and Ted Yednock, but they raised $34m in a Series A-1 venture capital funding round to advance drugs for neurodegenerative diseases.

Annexon was founded in 2011 and received seed funding from the Fidelity Biosciences Research Initiative, a philanthropic fund primarily focused...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category